| |
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save up to $500 with Early Bird Rates.Register Now! 
|
|
Today’s Big NewsJul 30, 2024 |
|
September 30- October 1, 2024 | Boston, MA Join the Fierce Biotech Summit to explore biotech's recovery and future. This two-day event features leaders discussing biotech IPOs, cell therapy, regulatory challenges, and strategic innovations. Connect with experts and gain valuable industry insights. Save up to $500 with Early Bird Rates. Register Now! 
|
|
| By Nick Paul Taylor Pfizer’s phase 3 Duchenne muscular dystrophy (DMD) gene therapy failure has blown a $230 million hole in the New York pharma's second quarter financials. The drugmaker disclosed the discontinuation of the candidate—and the financial fallout—alongside the axing of a respiratory syncytial virus (RSV) combination vaccine. |
|
|
|
By James Waldron For the second quarter in a row, Incyte has used its earnings results to significantly slim down its early-stage pipeline as the Jakafi-maker channels its resources toward “high potential impact programs.” |
By Nick Paul Taylor BioNTech has posted an early win for BNT111, linking a combination of the cancer vaccine candidate and Regeneron’s checkpoint inhibitor Libtayo to a better response rate than a historical control in melanoma patients. |
Sponsored by InMed Pharmaceuticals InMed Pharmaceuticals recently released preclinical data indicating its proprietary, small molecule compound, INM-901, targets multiple biological pathways associated with Alzheimer’s disease. |
|
Maximize Your Brand Exposure From brand awareness to lead generation, our tailored marketing solutions help you achieve your objectives. Get noticed, start conversations, and drive demand with Fierce Biotech. Learn more now. 
|
|
By Gabrielle Masson Immunology biotech VBI Vaccines is veering dangerously close to the point of no return, with plans to file for bankruptcy and sell off its assets. |
By James Waldron It’s not easy to muscle in on a space as competitive as immunology, but Celldex Therapeutics believes that its latest phase 2 win in a chronic form of hives means it has a shot at carving out its own niche. |
By Darren Incorvaia Toxoplasma gondii is a protozoan parasite famous for its cunning ways. This microbial manipulator can only reproduce inside of cats, so, if it finds itself in another mammalian host, like a rat, it alters the rodent’s behavior to make it less fearful of felines. Now, researchers have devised a way to engineer this single-celled saboteur for good. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Kevin Dunleavy With the BIOSECURE Act on the verge of passage and bringing with it the threat of crippling the business of four Chinese companies, the largest of the group, manufacturing powerhouse WuXi AppTec has reported a revenue decline. In the first half of 2024, sales for WuXi AppTec fell by 9%, to 17.2 billion yuan ($2.4 billion) year over year. |
By Noah Tong Expecting more variation in stand-alone prescription drug plan bidding, CMS is introducing a new voluntary program aimed at stabilizing premiums to thwart a turbulent enrollment period. |
By Kevin Dunleavy A month after a Centers for Disease Control and Prevention (CDC) panel narrowed its recommendations for who should receive vaccines to protect against respiratory syncytial virus (RSV), Airfinity has put numbers to the long-term impact. The London-based healthcare analytics company has sliced the RSV market value for seniors in the US from $4.7 billion to $1.7 billion in 2030. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong highlights some of the most promising companies that made our prestigious Fierce 15 list back in 2014. |
|
|---|
|
|
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria. 
|
|
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
